Moderna Inc (MRNA) has hosted a virtual Vaccines Day- following which four analysts reiterated their buy ratings on the stock. Roth Capital’s Yasmeen Rahimi also boosted her MRNA price target from $33 to $41. This wave of bullish sentiment sent shares soaring over 7% in Wednesday’s trading.At the event company management and infectious disease key opinion leaders discussed scientific, regulatory, and commercial considerations with respect to Moderna’s vaccine programs and the vaccine space more broadly.“Not surprisingly, SARS-CoV-2, the virus behind the Covid-19 outbreak featured prominently, with discussions of the virus itself, Moderna’s clinical plan (now enrolling the highest [250 µg] …read more
Source:: Yahoo Finance
